Research Excellence Award
Mark Shahin
Penn State Hershey Medical Center, United States
| Mark Shahin |
| Affiliation |
Penn State Hershey Medical Center |
| Country |
United States |
| Scopus ID |
7005839227 |
| Documents |
78 |
| Citations |
5,487 |
| h-index |
27 |
| Subject Area |
Emerging Technologies & Innovations |
| Event |
Engineering Scientist Awards |
| Google Scholar ID |
N3EZ0ZcAAAAJ&hl |
Mark Shahin is affiliated with Penn State Hershey Medical Center, United States, and has contributed extensively to clinical research involving gynecologic oncology, precision medicine, hereditary cancer genetics, and multidisciplinary cancer therapeutics. His scholarly record includes influential publications in leading peer-reviewed medical journals and collaborative participation in international clinical trials evaluating innovative therapeutic strategies. Based on his sustained research productivity, citation performance, and clinical impact, his profile represents a strong example of scientific excellence suitable for recognition through the Research Excellence Award.[1]
Abstract
Mark Shahin has established a distinguished academic record through collaborative oncology research emphasizing evidence-based cancer treatment, genomic medicine, and clinical trial innovation. His publications have contributed to improved understanding of ovarian, endometrial, and hereditary cancers while supporting advances in targeted therapies and personalized treatment approaches. His citation record demonstrates sustained scholarly influence across multiple areas of clinical oncology.[2]
Keywords
Gynecologic Oncology, Clinical Trials, Precision Medicine, Ovarian Cancer, Endometrial Cancer, Gene Therapy, Cancer Genetics, Emerging Technologies, Oncology Research, Translational Medicine.
Introduction
Modern oncology increasingly depends upon multidisciplinary collaboration to translate laboratory discoveries into effective patient care. Mark Shahin has participated in international research efforts addressing treatment optimization, inherited cancer risk assessment, and innovative therapeutic interventions. His work illustrates the growing integration of genomics, immunotherapy, and precision medicine into routine oncology practice.[3]
Research Profile
According to the provided bibliometric indicators, the researcher has authored 78 indexed publications with more than 5,487 citations and an h-index of 27. These metrics reflect consistent scholarly productivity and broad international collaboration. His work spans gynecologic oncology, hereditary cancer genetics, and therapeutic innovation, contributing to both clinical practice and academic literature.[1]
Research Contributions
- Contributed to landmark clinical trials investigating PARP inhibitors for advanced ovarian cancer.
- Participated in pivotal immunotherapy studies evaluating dostarlimab and pembrolizumab for endometrial cancer.
- Supported early investigations into p53 gene replacement therapy for recurrent ovarian cancer.
- Contributed to international consensus recommendations on inherited prostate cancer genetic testing.
Publications
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (NEJM, 2019).
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (NEJM, 2023).
- Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer (NEJM, 2023).
- A Phase I/II Trial of rAd/p53 Gene Replacement in Recurrent Ovarian Cancer (Cancer Gene Therapy, 2002).
- Role of Genetic Testing for Inherited Prostate Cancer Risk (Journal of Clinical Oncology).
Research Impact
The citation performance of Dr. Shahin’s publications indicates broad scientific influence within oncology. His participation in internationally recognized multicenter trials has supported the adoption of new therapeutic standards and strengthened evidence for personalized cancer treatment. These contributions continue to influence both research and clinical decision-making worldwide.[4]
Award Suitability
Considering the researcher’s publication record, citation metrics, collaborative leadership, and sustained contributions to oncology innovation, Mark Shahin demonstrates qualities commonly associated with recipients of research excellence recognitions. His scholarly achievements align with the objectives of the Engineering Scientist Awards in recognizing impactful scientific contributions supported by measurable academic influence.[5]
Conclusion
Mark Shahin’s academic profile reflects sustained excellence in clinical oncology research through high-quality publications, multidisciplinary collaboration, and measurable scholarly impact. His contributions to cancer therapeutics, genetics, and translational medicine continue to support advances in evidence-based healthcare and illustrate the characteristics expected of an internationally recognized research leader.
External Links
References
- Elsevier. (n.d.). Scopus Author Details: Mark Shahin, Author ID 7005839227.
https://www.scopus.com/authid/detail.uri?authorId=7005839227
- González-Martín A, et al. (2019). Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine.
https://doi.org/10.1056/NEJMoa1910962
- Mirza MR, et al. (2023). Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. New England Journal of Medicine.
https://doi.org/10.1056/NEJMoa2216334
- Eskander RN, et al. (2023). Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. New England Journal of Medicine.
https://doi.org/10.1056/NEJMoa2302312
- Buller RE, et al. (2002). A Phase I/II Trial of rAd/p53 Gene Replacement in Recurrent Ovarian Cancer. Cancer Gene Therapy.
https://doi.org/10.1038/sj.cgt.7700477